Becton, Dickinson and Co (BDX) has disclosed a new risk, in the Corporate Activity and Growth category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Becton, Dickinson and Co. faces significant risks in realizing the anticipated benefits from the merger of its Biosciences and Diagnostic Solutions business with Waters. The transaction may not deliver the expected operational, financial, and strategic advantages, potentially leading to increased expenses and diverted resources due to transition service commitments. Additionally, the transaction’s tax-free status for U.S. federal income tax purposes is uncertain, posing a risk of substantial tax liabilities. These factors could negatively impact the company’s business, financial condition, and operational results.
Overall, Wall Street has a Moderate Buy consensus rating on BDX stock based on 2 Buys and 5 Holds.
To learn more about Becton, Dickinson and Co’s risk factors, click here.